Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.
about
CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.Gene therapy for lysosomal storage disorders: a good start.Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC.Recent advances in gene therapy for lysosomal storage disorders.Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.Behavioral deficits and cholinergic pathway abnormalities in male Sanfilippo B miceHow close are we to therapies for Sanfilippo disease?Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.Targeting Root Cause by Systemic scAAV9-h Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice
P2860
Q27333793-35F258E2-B45C-4AC2-9C8F-22AF60A8B910Q33837598-6835104E-A0F2-4992-A830-F15F407636E3Q34502978-2AA9D5B9-9F07-4178-8D6F-033DFBD54550Q36649689-64CFA969-C139-4902-856C-10E17255D909Q37305882-DDB3FC0A-1D91-46AE-8DAF-E29660603E45Q38546492-C587ED6B-B915-4182-B601-1F14CAECF1CFQ38703339-771DCB74-C189-44E9-A28E-34D657DAB1C6Q38856794-B4C7FE4A-6722-40A3-8853-B5CFF1FF2157Q40277701-9A2351D8-7CC6-4852-B976-8A756071190AQ40482507-AD00D579-1D0B-49E1-842E-8BCD3C5410A0Q41633603-4DAE2C34-CB18-4791-9CE0-4D9A7AF4A0E1Q45872078-53283D55-E048-4DC2-A97B-7BAF8EF7C911Q45875162-1D88F45E-53EF-43B3-9996-2D62D470056EQ58765137-B0F5F559-A569-4239-9047-E4D3D8BE64E0
P2860
Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Biochemical, histological and ...... ebrospinal fluid gene therapy.
@en
Biochemical, histological and ...... ebrospinal fluid gene therapy.
@nl
type
label
Biochemical, histological and ...... ebrospinal fluid gene therapy.
@en
Biochemical, histological and ...... ebrospinal fluid gene therapy.
@nl
prefLabel
Biochemical, histological and ...... ebrospinal fluid gene therapy.
@en
Biochemical, histological and ...... ebrospinal fluid gene therapy.
@nl
P2093
P2860
P50
P356
P1476
Biochemical, histological and ...... ebrospinal fluid gene therapy.
@en
P2093
Christian Leborgne
Federico Mingozzi
Luca Maggioni
Martí Pumarola
Miguel Garcia
Pilar Villacampa
Sara Marcó
P2860
P304
P356
10.1093/HMG/DDU727
P50
P577
2014-12-18T00:00:00Z